American Association of Individual Investors3d
Why TG Therapeutics, Inc.’s (TGTX) Stock Is Up 10.20%
TG Therapeutics, Inc.’s TGTX share price has surged by 10.20%, which has investors questioning if this is right time to sell.
PipelineReview.com10d
Akeso Announces The Publication of Its Phase III Clinical Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab in The Lancet
HONG KONG, China I March 7, 2025 I Akeso, Inc. (9926.HK) ("Akeso" or the "Company")is excited to announce that the groundbreaking results of the Phase III ...
American Association of Individual Investors10d
Why ALX Oncology Holdings Inc.’s (ALXO) Stock Is Down 19.08%
ALX Oncology Holdings Inc.’s ALXO share price has dipped by 19.08%, which has investors questioning if this is right time to ...
Yahoo Finance10d
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
“In 2024, we delivered strong progress and continued momentum for our clinical development program evaluating evorpacept as a ...
Fierce Biotech11d
ALX lays off 30% of staff to pay for more trials of CD47 blocker
ALX Oncology is laying off 30% of its workforce as the biotech seeks to channel its cash into further trials of its CD47 ...
ALX Oncology will highlight progress across its clinical pipeline
ALX Oncology (ALXO) will highlight progress across its clinical pipeline, including continued advancement of investigational CD47-blocker ...
ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event
Event to include updates on ongoing evorpacept clinical development program and introduction of clinical trials in breast and ...
CURE14d
First Patient With Small Cell Lung Cancer Dosed With Peluntamig
The first patient with small cell lung cancer has been dosed in a trial of peluntamig (PT217) combined with chemotherapy.
Scientific Research Publishing17d
Zimarino, C., Moody, W., Davidson, S.E., Munir, H. and Shields, J.D. (2024) Disruption of CD47-SIRP
Cancer cells, when overexpressed with CD47, send a “don’t eat me” signal to macrophages, successfully shielding them from immune destruction. Similarly, tyrosine kinase inhibitors (TKIs) have ...
Scientific Research Publishing17d
Fu, Z., Feng, M., Wu, J., Liu, B., Fu, J. and Song, W. (2024) Photodynamic Therapy Synergizes CD47 Blockade Strategy for Enhanced Antitumor Therapy.
Cancer cells, when overexpressed with CD47, send a “don’t eat me” signal to macrophages, successfully shielding them from immune destruction. Similarly, tyrosine kinase inhibitors (TKIs) have ...
Targeted Oncology18d
Study Launches Exploring Peluntamig Combo in DLL3-Expressing Tumors
Dosing has started in a clinical evaluating peluntamig, which targets DLL3 and CD47, combined with chemotherapy in patients with DLL3-expressing cancers.